{
  "trial_metadata": {
    "trial_name": "PREVAIL",
    "nct_id": "NCT01212991",
    "publication_year": 2014,
    "indication": "Metastatic Castration-Resistant Prostate Cancer",
    "phase": "Phase III"
  },
  "arms_description": {
    "experimental_arm": "Enzalutamide 160 mg/day",
    "control_arm": "Placebo",
    "n_experimental": 872,
    "n_control": 845
  },
  "baseline_characteristics": {
    "median_age_exp": 72.0,
    "median_age_ctrl": 71.0,
    "sex_male_percentage_exp": 100,
    "sex_male_percentage_ctrl": 100,
    "ecog_0_percentage_exp": 67.0,
    "ecog_0_percentage_ctrl": 67.0
  },
  "efficacy_outcomes": {
    "primary_endpoint_data": {
      "endpoint_name": "Overall Survival",
      "hazard_ratio": 0.71,
      "ci_lower_95": 0.60,
      "ci_upper_95": 0.84,
      "p_value": 0.0001,
      "median_exp_months": 32.4,
      "median_ctrl_months": 30.2
    }
  },
  "safety_toxicity": {
    "any_grade_3_5_ae_rate_exp": 43.0,
    "any_grade_3_5_ae_rate_ctrl": 37.0,
    "discontinuation_rate_exp": 6.0,
    "discontinuation_rate_ctrl": 4.0,
    "serious_ae_rate_exp": 43.0,
    "serious_ae_rate_ctrl": 37.0
  }
}
